
    
      To assess the safety, tolerability and efficacy of HTL0018318 at 3 dose levels (once daily)
      compared with placebo over a 12-week treatment period in patients with dementia with Lewy
      bodies (DLB). Approximately 140 DLB patients who have not received donepezil (AriceptÂ®)
      and/or other acetyl cholinesterase inhibitors (AchEi) and approximately 32 DLB patients who
      have had prior treatment experience with donepezil but have stopped usage will be enrolled.
    
  